Sana Biotechnology

Sana Biotechnology R&D per Employee

The R&D Spending per Employee of Sana Biotechnology (SANA) as of Nov 16, 2026 is 929,436.62 USD. In the previous year, R&D Spending per Employee was 1.47 M USD — a change of -36.76% (lower).

R&D per Employee

929,436.62USD

YoY

-36.76%

Last updated:

R&D Spending per Employee of Sana Biotechnology is 2025 929,436.62 USD. R&D Spending per Employee of Sana Biotechnology was 2024 1.47 M USD. It decreases by -36.76% lower compared to the previous year.

The Sana Biotechnology R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
28,267.61 USD
Jan 1, 2019
840,669.01 USD
Jan 1, 2020
1.82 M USD
Jan 1, 2021
2.16 M USD
Jan 1, 2022
1.42 M USD
Jan 1, 2023
1.55 M USD
Jan 1, 2024
1.47 M USD
Jan 1, 2025
929,436.62 USD
The Sana Biotechnology R&D per Employee history
YEARR&D per EmployeeYoY
929,436.62USD-36.76%
1.47 MUSD-5.08%
1.55 MUSD+9.37%
1.42 MUSD-34.42%
2.16 MUSD+18.85%
1.82 MUSD+116.02%
840,669.01USD+2,873.97%
28,267.61USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sana Biotechnology Stock analysis

What does Sana Biotechnology do? Sana Biotechnology, Inc. develops engineered cell therapies as medicine, focusing on ex vivo and in vivo cell engineering platforms for unmet treatment needs in oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders. The company's most advanced product candidate is SC291, a CD19-directed allogeneic CAR T program for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. SC262, a CD22-directed allogeneic CAR T, and SC255, a BCMA-directed allogeneic CAR T for multiple myeloma, are also in development. Sana applies its hypoimmune technology to donor-derived T cells for allogeneic cell therapies targeting hematologic malignancies. Sana Biotechnology's revenue streams primarily come from research and development partnerships with pharmaceutical companies and biotechnology firms seeking to advance cell therapy platforms. These partners fund clinical trials and platform development, leveraging Sana's hypoimmune technology and engineered cell platforms to address complex therapeutic areas. The company's focus on allogeneic cell therapies, particularly for hematologic malignancies, attracts interest from major biopharma players aiming to expand their oncology portfolios. The primary customers for Sana's technology are pharmaceutical companies and biotechnology firms, especially those with oncology divisions seeking to develop next-generation cell therapies. These partners typically pay for access to Sana's platforms, including hypoimmune technology and engineered cell platforms, to accelerate their own drug development pipelines. The company's product candidates, such as SC291, SC262, and SC255, are positioned to enter clinical trials and eventually reach patients, generating potential future revenue through partnerships and eventual commercialization. Sana Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sana Biotechnology stock

R&D Spending per Employee of Sana Biotechnology is 929,436.62 USD in 2025.

R&D Spending per Employee of Sana Biotechnology changed from 1.47 M USD to 929,436.62 USD, representing a -36.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Sana Biotechnology since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Sana Biotechnology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Sana Biotechnology

All Key Metrics — Sana Biotechnology